A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients
Parkinson's Disease
About this trial
This is an interventional treatment trial for Parkinson's Disease focused on measuring Freezing of Gait
Eligibility Criteria
Inclusion Criteria:
- Parkinsonian patient with Parkinson's disease per UK brain bank criteria 15,
- or PSP per SPSP-NINDS criteria 16,
- FOG at off or on dopaminergic medication or both.
Exclusion Criteria:
- Patients with psychosis,
- unable to walk without assistance,
- seizures,
- or allergy to any of these three medications on trial.
Sites / Locations
- University of Chicago Medical Center
Arms of the Study
Arm 1
Other
Open-Label Treatment Arm
Each patient will take Duloxetine 30mg for 1 week, followed by 60mg qam for 1 week, 90mg qam for 1 week, and 120mg qam for 1 week, if tolerated. The patient will be taking Duloxetine for a total of 4 weeks. The dose of Duloxetine will be reduced if the patient cannot tolerate. Donepezil will then be added to Duloxetine 120mg qam (or the highest dose the patient can tolerate) by 5mg qd for 1 week, followed by 10mg qd for 1 week. After a 4-week washout period, each patient will take Modafinil 100mg qam for one week, followed by 200mg qam for 1 week. Patients will come into the medical center on 5 occasions, 1 for screening/baseline, 1 after completion of duloxetine, 1 after completion of duloxetine+donepezil, 1 after four-week washout, 1 after completion of modafinil.